In this article, we will explore 10 penny stocks with potential to rise 1000 percent.
Penny stocks can produce eye-catching bursts of upside, but their record against the broader market is usually weaker once you zoom out. Using BlackRock ETF proxies for comparison, the iShares Micro-Cap ETF returned 22.8% in 2025, ahead of the iShares Core S&P 500 ETF’s 17.9%, but over 10 years, the micro-cap fund annualized 9.4% versus 14.8% for the S&P 500 proxy. Risk was also much higher: the micro-cap fund’s three-year standard deviation was 22.5%, versus 12.0% for the S&P 500 fund. The SEC also notes that penny stocks tend to be less liquid, more volatile, and easier to manipulate, while academic work on lottery-like stocks has generally found lower future returns despite their appeal to speculators.
A large share of penny-stock growth stories tends to cluster in biotech and AI for structural reasons. In BlackRock’s micro-cap proxy, health care was the largest sector at 30.4%, while information technology accounted for 15.1%. Biotech fits the penny-stock mold because many firms are pre-revenue, cash-burning, and valued mainly on clinical milestones rather than current earnings. AI attracts similar speculative flows from the other direction: investors are trying to price in a rapidly expanding market, with Gartner projecting global AI spending of $2.52 trillion in 2026, up 44% year over year. In both cases, small companies can move sharply because expectations shift faster than fundamentals.
Source: Freepik
Methodology
We used consensus sentiment from Wall Street analysts and financial media websites to compile our list of penny stocks with the potential to rise 1000 percent over the next few years. We then limited our final selection to companies that have recently reported noteworthy developments likely to affect investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent.
On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also makes KRESLADI the first FDA-approved gene therapy for this condition, which gives Rocket a commercial foothold in an ultra-rare disease market.
The bigger takeaway is what came with the approval. Rocket said it also received a Rare Pediatric Disease Priority Review Voucher, an asset biotech companies can monetize, and management said it is evaluating strategic options for the voucher to enhance financial flexibility. The company added that it plans to make KRESLADI available to eligible U.S. patients.
Rocket has also been signaling a measured launch rather than a broad commercial push. Recent company disclosures described a scaled commercial effort tailored to the very small patient population, while Reuters reported the rollout is expected to begin through a limited number of specialized centers. As of December 31, 2025, Rocket had $188.9 million in cash, cash equivalents, and investments.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company focused on genetic therapies for rare disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.
9. Datavault AI Inc. (NASDAQ:DVLT)
Datavault AI Inc. (NASDAQ:DVLT) is one of the penny stocks with the potential to rise 1000 percent.
On March 19, 2026, Datavault AI reported its first profitable quarter and record revenue growth for fiscal 2025. The company said fourth-quarter revenue reached $33.8 million, up 3,650% year over year, while operating profit improved to $4.2 million from a $6.3 million loss a year earlier. It also reported a net profit of $661 thousand for the quarter, which it described as the first in its history. For the full-year 2025, revenue rose 1,362% to $39.1 million, while gross profit reached $30 million, with a gross margin of about 78%.
The company also pointed to a stronger balance sheet at year-end, with about $116 million in working capital, $142.9 million in current assets, $26.9 million in current liabilities, and no long-term debt. On outlook, Datavault AI reiterated its full-year 2026 revenue target of $200 million, which it said would represent nearly 400% year-over-year growth from fiscal 2025. That target is management guidance and, as the company noted, remains subject to forward-looking risks and uncertainties.
Datavault AI Inc. (NASDAQ:DVLT) develops AI-driven data monetization, credentialing, digital engagement, and tokenization technologies through its Acoustic Sciences and Data Sciences divisions. The company is headquartered in Philadelphia.
8. Vertical Aerospace (NYSE:EVTL)
Vertical Aerospace (NYSE:EVTL) is one of the penny stocks with the potential to rise 1000 percent.
On March 27, Vertical Aerospace said it selected Italy-based Isoclima S.p.A. as a strategic supplier for the full transparency suite on its Valo aircraft, including pilot and passenger canopies and glazing systems. The company said the long-term partnership is intended to support the program through certification, production, and entry into commercial service, while adding Isoclima to a supplier roster that already includes Honeywell, Aciturri, Evolito, and Syensqo.
Vertical said aircraft transparencies must meet requirements including bird-strike resistance, structural loads, and environmental stress while maintaining visibility standards. It said the agreement is intended to provide supply stability and technical continuity as development of Valo advances.
In a March 24 update, Vertical said transition testing for Valo is underway and that it is now focused on certification and scaling production. The company also said it expects approximately $195 million of net cash outflows over the next 12 months as it increases investment in flight testing, certification, and manufacturing. In a separate March 18 release, Vertical said its battery pilot production line had become operational.
Vertical Aerospace (NYSE:EVTL) is a global aerospace and technology company pioneering electric aviation. Valo is a piloted, four-passenger eVTOL aircraft, and the company says it has about 1,500 pre-orders across four continents.
7. Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Jasper Therapeutics Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent.
UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term durability data, with limited near-term catalysts, before topline data from the BEACON Phase 2b study in chronic spontaneous urticaria, or CSU, expected in 2027.
The call came after Jasper had already reported updated data for briquilimab on January 8. The company said 67% of additional patients treated with briquilimab in the BEACON Phase 1b/2a study achieved a complete response at 12 weeks, while 83% achieved a complete response by week 3 after the initial dose. Jasper also said the BEACON and open-label extension data were enough to support dose selection for a Phase 2b study in CSU planned to begin in the second half of 2026.
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting KIT (CD117), for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
6. Gossamer Bio, Inc. (NASDAQ:GOSS)
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent.
Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary endpoint, though the company said it planned to meet with the U.S. Food and Drug Administration to discuss a potential path forward and paused enrollment in the SERANATA study while it reviewed the data.
Even after cutting their price targets, both Oppenheimer and H.C. Wainwright kept bullish ratings on the stock. On March 5, Oppenheimer maintained its Outperform rating and lowered its target to $3 from $12. On March 6, H.C. Wainwright maintained its Buy rating and cut its target to $5 from $10. Based on Gossamer Bio’s recent share price of about $0.37, Oppenheimer’s target still implied upside of more than 700%, while H.C. Wainwright’s target implied upside of more than 1,200%.
Public summaries of the H.C. Wainwright update noted that analyst Patrick Trucchio reduced the estimated probability of success for seralutinib in PAH to 50% from 70%. Even so, later reporting on the firm’s view said the data still “demonstrate evidence of clinical activity,” particularly in heavily pretreated patients, and that “a path forward may yet emerge,” although regulatory and capital uncertainty would likely remain an overhang.
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension and other serious diseases.
While we acknowledge the potential of GOSS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GOSS and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Penny Stocks with Potential to Rise 1000 Percent.
Disclosure: None. Follow Insider Monkey on Google News.
